Sunday, May 5, 2019

Lexicon Pharmaceuticals Languishing In The Dog House

Fool me once, shame on you. Fool me twice, shame on me. Disappoint investors over a period of decades? Well, then you’re Lexicon Pharmaceuticals (LXRX). Yes, that’s snarky and mean, and not everything that has happened to this company is the fault of management, but in terms of real world, on-the-ground results, just look at a 10-year chart next to one of the biotech indices like the IBB (IBB).

Lexicon once again posted disappointing results for its only commercial drug, and offered no additional clarity on the path forward for the Type 1 diabetes indication of Zynquista. Although the European approval is nice-to-have, Lexicon’s economics are best on the Type 1 U.S. indication, and that’s the needle-mover in my model. While Lexicon does have some early-stage clinical compounds worth following, it’s going to take time for this story to turn around.

Click here for more:
Lexicon Pharmaceuticals Languishing In The Dog House

No comments: